Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advanced<em>EGFR</em>mutation-positive lung adenocarcinoma

金　波; 张岩巍; 韩宝惠

doi:10.3969/j.issn.1007-3969.2015.10.001

您当前的位置：

首页 >

文章列表页 >

Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advancedEGFRmutation-positive lung adenocarcinoma

更新时间：2025-12-31

- Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advancedEGFRmutation-positive lung adenocarcinoma
- China Oncology Vol. 25, Issue 10, Pages: 761-767(2015)
- 作者机构：
  
  上海交通大学附属胸科医院呼吸内科,上海,200030
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2015.10.001
  CLC：
- Published Online：17 December 2015，
  
  Published：17 December 2015
- 稿件说明：
移动端阅览
金　波,张岩巍,韩宝惠,等.

金　波, 张岩巍, 韩宝惠. Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advancedEGFRmutation-positive lung adenocarcinoma[J]. China Oncology, 2015, 25(10): 761-767.
金　波,张岩巍,韩宝惠,等. DOI： 10.3969/j.issn.1007-3969.2015.10.001.

金　波, 张岩巍, 韩宝惠. Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advancedEGFRmutation-positive lung adenocarcinoma[J]. China Oncology, 2015, 25(10): 761-767. DOI： 10.3969/j.issn.1007-3969.2015.10.001.

摘要

背景与目的：表皮生长因子受体(epidermal growth factor receptor，EGFR)敏感突变的晚期肺腺癌患者目前标准一线治疗方案为表皮生长因子受体-酪氨酸激酶抑制剂(epithelial growth factor receptor-tyrosine kinase inhibitor，EGFR-TKI)单药治疗。该研究探索化疗联合吉非替尼与单用化疗、单用吉非替尼在EGFR基因敏感突变的晚期肺腺癌一线治疗中的疗效及安全性比较。方法：本研究共纳入了61例EGFR基因敏感突变(19外显子缺失突变或21外显子L858R点突变)、PS 0～1分的初治晚期肺腺癌患者，并用随机数字法随机分成3组。A组20例，给予AC方案化疗(培美曲塞500 mg/m

，第1天；卡铂AUC 5，第1天)联合口服吉非替尼(250 mg/d，第5~21天)，每4周为1个周期，最多6个周期，然后每4周进行1次培美曲塞单药联合吉非替尼口服(用药方法及剂量同前)维持治疗；B组20例，给予AC方案化疗(培美曲塞500 mg/m

，第1天；卡铂AUC 5，第1天)，每4周为1个周期，最多6个周期，然后每4周进行1次培美曲塞单药维持治疗；C组21例，口服吉非替尼治疗(250 mg/d)。3组的治疗均持续至患者出现疾病进展或出现无法耐受的不良反应或死亡。研究的主要终点为中位无进展生存时间(progression-free survival，PFS)和12个月PFS率，次要终点为总体缓解率、安全性/不良反应。结果：随访中A、C组各失访1例。A组患者中位PFS为20.1个月(95%CI：18.0～22.2个月)，B组患者中位PFS为5.5个月(95%CI：3.9～7.2个月)，C组患者中位PFS为9.8个月(95%CI：6.8～12.8个月)。A组的12个月PFS率为78.9%，B组为15.0%，C组为40.0%。总体缓解率：A组为84.2%，B组为35.0%，C组为65.0%。安全性方面，严重不良反应的发生率A组为36.8%，B组为30.0%，C组为5.0%。最常见的3～4度不良反应为中性粒细胞减少(A组3例、B组4例)、乏力(A组2例、B组2例)及肝功能损害(A组2例、C组1例)。结论：一线接受化疗与吉非替尼联合治疗的EGFR敏感突变的晚期肺腺癌患者PFS更长。长期的生存结果仍在进一步随访中。

Abstract

Background and purpose: For patients with advanced lung adenocarcinoma harboring an activating EGFR gene mutati

the current standard of care is EGFR-TKI alone. This study aimed to compare efficacy and safety of gefitinib plus chemotherapy with gefitinib or chemotherapy alone for treating advanced lung adenocarcinoma with an activating EGFR gene mutation. Methods: This study included 61 patients with lung adenocarcinoma harboring an activating EGFR gene mutation (19 exons deletion and exon 21 L858R mutations) whose ECOG performance status was 0 or 1. Patients were randomly divided into 3 groups. Group A (n=20) were given carboplatin/pemetrexed of a 4-week cycle

six cycles at most

plus gefitinib (pemetrexed 500 mg/m

d1; carboplatin AUC 5

d1; gefitinib 250 mg/d

d 5-21)

and then received pemetrexed of a 4-week cycle plus gefitinib as maintenance therapy; Group B (n=20) were given carboplatin/pemetrexed of a 4-week cycle

six cycles at most (pemetrexed 500 mg/m2

d1; carboplatin AUC 5

d1)

then received pemetrexed as maintenance therapy; Group C (n=21) were given gefitinib (gefitinib 250 mg/d). Patients continued to receive therapy until disease progression or unacceptable toxicity or death. The primary end point was middle PFS and 12 months PFS rate. The secondary end points included objective response rate and adverse events. Results: Groups A and C both lost 1 case during follow-up. Median PFS for patients was 20.1 months (95%CI:18.0-22.2) in group A

5.5 months (95%CI:3.9- 7.2) in group B

and 9.8 months (95%CI:6.8-12.8) in group C. PFS rates of 12 months for groups A

B and C were 78.9%

15.0% and 40.0%

respectively. The overall objective response rates for groups A

B and C were 84.2%

35.0% and 65.0%

respectively. Serious adverse events were reported by 36.8% for group A

30.0% for group B

and 5.0% for group C. The most common grade 3/4 adverse events were neutropenia (3 cases in group A

4 cases in group B)

fatigue (2 cases in group A

2 cases in group B) and liver function impairment (2 cases in group A

1 case in group C). Conclusion: Among patients with EGFR mutant lung adenocarcinoma

comb

ination of chemotherapy with gefitinib as first-line treatment demonstrates an improvement in PFS. Long-term survival results will be further followed up.

关键词

Keywords

references

Views

2107

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Predictive value of logistic regression model based on high-resolution CT signs for high-grade pattern in stage ⅠA lung adenocarcinoma

Effects of lncRNA PKD2-2-3 on cell proliferation, clone formation, migration, and invasion of lung adenocarcinoma

Analysis of differential splicing gene by regulation of splicing regulatory protein KHSRP in lung adenocarcinoma

Development and validation of a nomogram for predicting spread through air spaces in stage ⅠA lung adenocarcinoma

The role and application value of integrin β3 in bone metastasis of lung adenocarcinoma

Related Author

Hao DONG

Yonggang QIU

Xinbin WANG

Junjie YANG

Cuncheng LOU

Lekang YIN

Xiaodan YE

Liqing JIA

Related Institution

Department of Cancer Center, Zhongshan Hospital, Fudan University

Department of Radiology, First People's Hospital of Xiaoshan District

Department of Pathology, First People's Hospital of Xiaoshan District

Department of Radiology, Zhongshan Hospital, Fudan University

Shanghai Institute of Medical Imaging

AI问答

⁰

Randomized controlled trial of chemotherapy plus gefitinib as first-line treatment for patients with advancedEGFRmutation-positive lung adenocarcinoma

DOI：10.3969/j.issn.1007-3969.2015.10.001

摘要

Abstract

关键词

Keywords

references